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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Methods: We developed novel protocols for extracting renal lym-
phocytes from healthy kidney tissue and diseased biopsies with and
without ﬁbrosis. Lymphocyte subsets were identiﬁed, enumerated
and phenotyped by twelve-colour ﬂow cytometry.
Results: We detected signiﬁcantly elevated numbers of T cells
(CD45+CD3+) in diseased biopsies with interstitial ﬁbrosis
compared with healthy kidney tissue. Within this T cell compart-
ment, numbers of T helper cells (CD3+CD4+) and cytotoxic T cells
(CD3+CD8+) were elevated in ﬁbrotic kidney tissue. Moreover,
numbers of / T cells (CD3+ / +) and natural killer (NK)-T cells
(CD3+CD16+) were signiﬁcantly increased in ﬁbrotic biopsies
compared with diseased biopsies without ﬁbrosis and healthy
kidney tissue. Of CD3- lymphoid cells, NK cells (CD3-CD56+) were
elevated in ﬁbrotic kidney tissue, in particular CD56brightCD16-/+
NK cells, the major cytokine-producing NK subtype in human
peripheral tissues and secondary lymphoid organs. B cells (CD3-
CD19+) were also increased in ﬁbrotic kidney tissue. Additionally,
numbers of / T cells, NK-T, NK and B cells correlated with loss of
kidney function (based on eGFR levels). Expression of activation
molecule CD69 on renal lymphocytes was increased in ﬁbrotic bi-
opsies compared with healthy kidney tissue, indicative of a path-
ogenic phenotype.
Conclusions: Collectively, our data show that lymphocyte
subsets are differentially recruited into diseased human kid-
neys. The representation of speciﬁc lymphocyte subsets also
correlates with the clinical severity of chronic kidney disease.
Further identiﬁcation and functional dissection of these
lymphocyte subsets will enable the development of targeted
treatment strategies.
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Introduction: The lysosomal cysteine protease cathepsin (Cat)-S
processes the invariant chain-MHC II complex inside antigen-
presenting cells as a central pathomechanism of autoimmune dis-
eases. In addition, activated myeloid cells release Cat-S and was
recently described to activate protease-activated receptor (PAR)-2
in extracellular compartments (Kumar S, et al JASN 2015). We
hypothesized that in lupus nephritis Cat-S blockade can target both
pathomechanisms and can elicit synergistic therapeutic effects
disease outcomes.
Methods: Female MRL-Fas(lpr) mice with spontaneous autoimmune
tissue injury were treated with different doses of the oral Cat-S
antagonist RO5459072 or mycophenolate mofetil (MMF) or vehicle
from week 11 or 15 to 19 of age. To evaluate the Cat-S induced
micro-vascular damage, female MRL-Fas(lpr) mice were injected
with recombinant Cat-S with or without concomintant Cat-S or
PAR2 blockade and urine albumin levels were measured at different
time intervals. In-vitro studies with PAR2 expressing endothelial
cells were used to conﬁrm the Cat-S induced endothelial activation
and dysfunction.Kidney International Reports (2016) 1, S1–S22Results: Cat-S blockade dose-dependently protected aberrant sys-
temic autoimmunity, by reducing the plasma cytokine levels,
activation myeloid cells and lymphocytes, and hyper-
gammaglobulinemia. Especially IgG auto-antibodies were sup-
pressed. Of note while (MHC-II-independent) IgM antibodies were
not affected by Cat-S blockade but strongly suppressed by MMF.
Cat-S blockade dose-dependently suppressed immune complex
glomerulonephritis together with a profound and early effect on
proteinuria, which was not shared by MMF. In fact, intravenous
Cat-S injection induced severe glomerular endothelial cell injury
and albuminuria, which was entirely prevented by Cat-S or PAR2
blockade. In-vitro studies conﬁrm that Cat-S induces endothelial
cell activation and injury via PAR-2. PAR2 silencing in endothelial
cells using siRNA signiﬁcantly protected the endothelial injury in-
vitro.
Conclusions: Therapeutic Cat-S blockade suppresses synergistic
systemic and peripheral pathomechanisms of autoimmune tissue
injury, hence, Cat-S is a promising therapeutic in autoimmune
diseases.
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Introduction: Diabetic Nephropathy (DN) remains an unmet medi-
cal challenge as its prevalence is projected to continue to increase
and speciﬁc medicines for treatment remain undeveloped. Activa-
tion of the immune system, in particular T-cells, is emerging as a
possible mechanism underlying DN disease progression in humans
and animal models. We hypothesized that inhibition of T-cell
activation will ameliorate DN. Interaction of B7-1 (CD80) on the
surface of antigen presenting cells with its binding partners,
CTLA4 (CD152) and CD28 on T-cells, is essential for T-cell activa-
tion. In this study we used a soluble CTLA4-Fc fusion protein to
block cell surface B7-1, preventing the cellular interaction and
inhibiting T-cell activation.
Methods: The CTLA4-Fc Abatacept was dosed i.p. in the Strepto-
zotocin-induced Diabetic Nephropathy mouse model in both pre-
vention and intervention modes. Renal damage was assessed by
albuminuria and renal B7.1 positive cells and lymphocytes were
measured by immunohistochemistry. Gene expression interrogated
by real-time PCR and protein expression by Western blotting.
Differentiated human immortalized podocytes were used for in
vitro studies.
Results: When CTLA4-Fc was dosed in an animal model of DN, it
reduced albuminuria in both prevention and intervention modes.
The number of T-cells inﬁltrating the kidneys of DN animals
correlated with the degree of albuminuria and treatment with
CTLA4-Fc reduced the number of renal T-cells. As B7-1 induction
has been recently proposed to underlie podocyte damage in DN,
CLTA4-Fc could be efﬁcacious in DN by protecting podocytes.
However, this does not appear to be the case as B7-1 was not
expressed in: 1) kidneys of DN animals; 2) stimulated human
podocytes in culture; or 3) glomeruli of DN patients.
Conclusions: We conclude that CTLA4-Fc ameliorates DN by
blocking T-cell activation and not by protecting podocytes.S17
